MedTrace Logo

Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma

NCT03280667 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2023-03-29

No results posted yet for this study

Summary

This Single-arm, multicentre, phase 2 trial aims determine the activity and safety of pembrolizumab and denosumab in advanced clear cell renal cell carcinoma (ccRCC).

Conditions

  • Renal Cell Carcinoma, Clear Cell
  • Metastatic Kidney Cancer

Interventions

DRUG

Pembrolizumab plus denosumab

Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Amgen

    collaborator INDUSTRY

  • Australian and New Zealand Urogenital and Prostate Cancer Trials Group

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-12
Primary Completion
2023-06-04
Completion
2023-06-04

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03280667 on ClinicalTrials.gov